Patients in the study had suffered a second relapse with duration of second response less than six months, or had been refractory to two previous courses of induction chemotherapy. There currently are no approved therapies for treating third-line adult AML patients and the historical median survival time is approximately two months.
“Although we are disappointed with the results of Troxatyl in this very difficult to treat third-line AML population, Troxatyl has produced interesting clinical results in other indications and we remain optimistic for its potential in these other indications. We will now analyze data from all patients treated thus far in the phase II/III trial and will be taking a careful look at the range of opportunities to determine an appropriate development path for Troxatyl,” said Mike Grey, president and CEO of SGX Pharmaceuticals.